35 completed, 22 unknown, 18 recruiting, 13 not yet recruiting. 40 Phase 2, 21 Not applicable, 17 Phase 3, 4 Phase 4, 2 Early Phase 1.
Follow Endometrial Hyperplasia: new trials by email Literature Review of Endometrial Hyperplasia trials Research Report on Endometrial Hyperplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer Semaglutide (Wegovy) weekly injection, LNG-IUD (Progestin), Structured Weight Loss Program - Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia | Phase 2 | Not yet recruiting | The Methodist Hospital Research Institute | 48 | 2027-01-01 | 2026-10-01 |
| Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer Tirzepatide - Endometrial Cancer, Endometrial Intraepithelial Neoplasia | Phase 2 | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 40 | 2027-01-01 | 2026-09-28 |
| SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer GLP-1 Receptor Agonist, Levonorgestrel IUD (Lng-IUD), Oral Progestins - Endometrial Cancer, Endometrial Cancer Stage I | Phase 4 | Not yet recruiting | Hospital Universitari de Bellvitge | 80 | 2027-01-01 | 2026-06-10 |
| Canagliflozin Plus Progestin for Atypical Endometrial Hyperplasia and Early-Stage Endometrial Cancer LNG-IUS: levonorgestrel intrauterine system, Metformin, Canagliflozin - Endometrioid Endometrial Cancer, Atypical Endometrial Hyperplasia | Phase 2 | Not yet recruiting | Wang Yingmei | 102 | 2027-01-01 | 2026-10-22 |
| Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer Tirzepatide - Grade 1 Endometrial Endometrioid Carcinoma, Endometrial Intraepithelial Neoplasia | Early Phase 1 | Not yet recruiting | Milton S. Hershey Medical Center | 15 | 2026-11-01 | 2026-09-10 |
| Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer Mazdutide(Dual GLP-1R/GCGR Agonist), Placebo, Levonorgestrel-releasing intrauterine system - Obesity, Overweight | Phase 2 | Not yet recruiting | Tongji Hospital | 128 | 2026-11-01 | 2026-08-24 |
| A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer Medical Device Usage and Evaluation, Tirzepatide - Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 55 | 2026-11-01 | 2026-08-26 |
| Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia Orlistat, Progestin - Endometrial Neoplasms, Endometrial Cancer | Phase 2 | Not yet recruiting | Peking University People's Hospital | 48 | 2026-07-01 | 2026-07-20 |
| Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial Biopsy Procedure, Curettage Procedure, Hysterectomy - Endometrial Endometrioid Adenocarcinoma, Endometrial Hyperplasia | Phase 2 | Recruiting | New Mexico Cancer Research Alliance | 140 | 2026-06-15 | 2026-07-02 |
| Measurement of Urinary Hormones in Patients With Abnormal Uterine Bleeding to Study Uterine Cancer Progression Uterine Bleeding, Uterine Cancer | Not yet recruiting | University of British Columbia | 50 | 2026-05-01 | 2026-05-12 | |
| A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia Glucagon-like peptide 1 receptor agonist - Endometrioid Endometrial Adenocarcinoma | Phase 2 | Recruiting | University of Florida | 20 | 2026-04-07 | 2026-10-21 |
| Endometrial Cancer Vaginal Fluid Specimen Collection Study Abnormal Uterine Bleeding (AUB), Endometrial Cancer | Active not recruiting | Exact Sciences Corporation | 4200 | 2026-03-10 | 2026-10-05 | |
| Intrauterine Injection of Type III Collage in FST of EC/AEH Recombinant Humanized Type III Collagen Lyophilized Fibers + High-dose Progestin, High-dose Progestin - Atypical Endometrial Hyperplasia, Endometrial Cancer | Phase 2 | Recruiting | Wang Jianliu | 30 | 2026-01-30 | 2026-03-30 |
| Cervical Cytology DNA Methylation for Endometrial Lesion Screening and Follow-up Endometrial Neoplasms, DNA Methylation | Not yet recruiting | Peking Union Medical College Hospital | 3500 | 2026-01-10 | 2025-12-23 | |
| Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months BAY865028, Medroxyprogesterone acetate - Endometrial Hyperplasia | Phase 3 | Withdrawn | Bayer | 2025-11-24 | 2026-07-30 | |
| POPQ Associated With Total Laparoscopic Hysterectomy Questionnaire and Physical Exam - Uterine Fibroids (UF), Abnormal Uterine Bleeding Unrelated to Menstrual Cycle | Not yet recruiting | Medical University of Silesia | 2000 | 2025-10-01 | 2025-08-22 | |
| Cohort Study of Intrauterine Diseases No intervention (observational study) - Endometrial Cancer, Endometrial Hyperplasia | Recruiting | Wenwen Wang | 2000 | 2025-07-01 | 2025-07-02 | |
| Surgical and Obstetric Outcomes in Endometrial Adenocarcinoma and Atypical Endometrial Hyperplasia With Conservative Treatment Hysteroscopic Resection and Hormonal Therapy - Endometrial Adenocarcinoma, Endometrial Hyperplasia | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 100 | 2025-06-20 | 2025-07-22 | |
| Ultrasound and Histology in AEH and Early EEC Treated Conservatively Hysteroscopic fertility-sparing surgery and hormonal treatment - Fertility-Sparing Treatment (FST), Atypical Endometrial Hyperplasia | Not yet recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 50 | 2025-06-11 | 2025-06-19 | |
| Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia Semaglutide, Placebo, LNG-IUD (Progestin) - Endometrial Hyperplasia | Phase 2 | Withdrawn | Washington University School of Medicine | 2025-03-12 | 2026-01-12 |
Showing 20 of 103. Sign in to see all of them.
Endometrial Neoplasms (58) · Obesity (11) · Metrorrhagia (5) · Infertility (4) · Overweight (4) · Uterine Diseases (4) · Leiomyoma (3) · Pelvic Organ Prolapse (3) · Progesterone Resistance (3) · Uterine Cervical Dysplasia (3) · Uterine Hemorrhage (3) · Breast Neoplasms (2) · Hyperplasia (2) · Myofibroma (2)
Female Urogenital Diseases (103) · Female Urogenital Diseases and Pregnancy Complications (103) · Genital Diseases (103) · Genital Diseases, Female (103) · Urogenital Diseases (103) · Uterine Diseases (99) · Neoplasms (62) · Neoplasms by Site (59) · Genital Neoplasms, Female (58) · Urogenital Neoplasms (58) · Uterine Neoplasms (56) · Pathological Conditions, Signs and Symptoms (29) · Signs and Symptoms (16) · Nutritional and Metabolic Diseases (14) · Pathologic Processes (14)
Megestrol Acetate (15) · Metformin (7) · Medroxyprogesterone Acetate (6) · Progestins (6) · Levonorgestrel (5) · Biopsy (3) · Estrogens, Conjugated (USP) (3) · Letrozole (3) · Tirzepatide (3) · semaglutide (3) · Atorvastatin (2) · Blood Specimen Collection (2) · Hysterectomy (2) · Hysteroscopy (2) · Intrauterine Devices (2)
Xiaojun Chen (6) · Peking University People's Hospital (5) · Fudan University (4) · Imperial College London (3) · Milton S. Hershey Medical Center (3) · National Cancer Institute (NCI) (3) · University of Campania Luigi Vanvitelli (3) · Bayer (2) · Dana-Farber Cancer Institute (2) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (2) · Kayseri Education and Research Hospital (2) · Korean Gynecologic Oncology Group (2) · M.D. Anderson Cancer Center (2) · Sohag University (2) · UNC Lineberger Comprehensive Cancer Center (2)
United States (27) · China (20) · Italy (9) · Egypt (6) · United Kingdom (5) · Canada (3) · South Korea (3) · Turkey (Türkiye) (3) · Israel (2) · Australia (1) · Austria (1) · France (1) · Honduras (1) · Indonesia (1) · Iraq (1)
Andrea R Hagemann, M.D., MSCI (2) · Richard Legro, M.D. (2) · Amr Alnemr, M.D. (1) · Andreas Obermair (1) · Antonia Carla Testa (1) · Aparna A. Kamat, MD (1) · Arie Lissak, MD (1) · Boris Kaplan, prof (1) · Britt K Erickson (1) · Brunella Ms Zizolfi, AssProfessor (1) · Bumi Herman, Ph.D (1)
PMID 32909630, PMID 11437723, PMID 12466350, PMID 17100821, PMID 18928975, PMID 19635615, PMID 19921229, PMID 23985562, PMID 24286192, PMID 26905333, PMID 27676118, PMID 29953784, PMID 30147382, PMID 30675969, PMID 31591361, PMID 32266800, PMID 32805208, PMID 33009021, PMID 33412129, PMID 33762086, PMID 37182434, PMID 37431855, PMID 38425141, PMID 39215793, PMID 40669559, PMID 41286566, PMID 41721625, PMID 41956247
P50CA098258 (2), N01CM62201 (1), N01CN00033 (1), P01CA278735 (1), P01HL045666 (1), P30CA012197 (1), P30CA014089 (1), P30CA014520 (1), P30CA016672 (1), P30CA033572 (1), P30CA060553 (1), P30CA118100 (1), P50CA265793 (1), U01CA281026 (1), U10CA101165 (1)